In February the project started on-site in 7 of a total of 26 primary schools and high schools that are taking part in the Sentinel Schools Study. The project is being set up and coordinated by the CEEISCAT, a research group at the IGTP that aims to monitor and evaluate the covid-19 pandemic in schools in Catalonia in order to be able to design health and education policies for the immediate future.
At the IGTP TODAY
11 March is World Kidney Day and this year it is focussing on quality of life for people living with kidney disease. Currently 10% of the world population is affected by chronic renal disease (CRD) and more than 2 million people receive dialysis or kidney transplants worldwide. At the Germans Trias i Pujol Research Institute (IGTP) the Kidney Disease Group and the Innovation in Vesicles and Cells for Application in Therapy Group (REMAR-IVECAT) led by Francesc Borràs is working on improving diagnosis and treatments for these diseases. The group studies biomarkers for non-invasive monitoring of the conditions in patients and they are also study the application of advanced therapies. In fact they are pioneers in the use of extracellular vesicles as a therapeutic tool for kidney disease.
The start of a new international clinical trial to improve treatment for tuberculosis with anti-inflammatory agents
The Experimental Tuberculosis Group at the IGTP has set up this trial, coordinated from Can Ruti, within the European project H2020 ‘SMA-TB’. The study will evaluate the efficacy and safety of adding acetylsalicylic acid or ibuprofen to the antibiotic treatments applied for tuberculosis. It is a phase II trial which will be carried out in South Africa and Georgia, two of the countries the WHO has in its sights to control this infectious disease. The trial has been prepared in the midst of the pandemic, with the added challenge of coordinating it with the restrictions and different stages of the epidemic in each of the countries involved.
New insights into the mechanisms of how tolerogenic therapies reduce aggressive immune activity in treatments for auto-immune and inflammatory diseases
The Immunopathology research group with the Immunology service and the Multiple Sclerosis Unit at the Germans Trias i Pujol Hospital and Institute continue their research to develop treatments for multiple sclerosis (MS). Their latest paper published in Frontiers of Immunology, examines the mechanisms by which vitamin D3-dendritic cells are used to alter a patient's own lymphocytes so they can be used to inhibit autoimmune responses.
SNCA transcripts found in blood are candidate biomarkers for Lewy body dementia and Parkinson disease
In a new study published in the Journal of Molecular Science, the Genomics and Transcriptomics of Synucleinopathies Group, led by Dr Katrin Beyer, have got one step nearer to finding a reliable biomarker to differentiate between Lewy body dementia and Parkinson disease in the early stages, when symptoms are very similar. Correct diagnosis is extremely difficult, but essential for these patients as the wrong treatment can have very serious effects.
As the research institute of the Germans Trias i Pujol Hospital, the IGTP is one of 8 health research institutes that has joined the ICFO to consolidate a state-of-the-art bench to bedside Barcelona Photonics Technology Network. The Medical Photonics Network of Barcelona was presented on 18 February, it aims to promote the research and development activities in photonics being carried out in the Barcelona area by formalizing the long-running relationship between the ICFO and its biomedical and clinical partners.
Can Ruti focuses on the effect of COVID-19 in the gender perspective in biomedical research to celebrate the International Day of Women and Girls in Science
The 3rd Celebration of the International Day of Women and Girls in Science at Can Ruti took place on Wednesday 10 February, organized by the multi-institutional working group "Women in Science (WiS)", and hosted by the IGTP. The symposium looked at data on the gender perspective of the effects of the Covid-19 pandemic presenting data from studies both on and off the campus and providing a platform for personal testimonies from men and women involved in research and healthcare.
Blocking the spread of HIV or favouring the spread of the tuberculosis bacteria, the flip side of the Siglec-1 protein's absence
In 2016, the Retrovirology and Clinical Studies group at IrsiCaixa discovered how the absence of the Siglec-1 protein, involved in modulating the immune system, blocks the spread of HIV throughout the body. Now, a study led by the same research group and the Experimental Tuberculosis Unit of the Germans Trias i Pujol Research Institute (IGTP) has shown that, on the other hand, this same deficiency favours the dissemination of Mycobacterium tuberculosis (Mtb), the tuberculosis-causing agent.
A new e-book published by the Journal Laboratory Equipment, called Safe and Effective Research in the Vivarium features a case study from the Centre for Comparative Medicine and Bioimage of the IGTP (CMCiB-IGTP). Staff from the CMCiB have provided expert advice on aspects of safety.
The Immunology of Diabetes Group, led by Marta Vives-PI has shown that levels of 4 subtypes of natural killer (NK) cells in the blood of Type 1 Diabetes patients change through different stages of the disease. These cells have a complex role in the immune attack during T1D and have been implicated in both the destruction and protection of insulin-producing cells. This pilot study, published in Frontiers in Immunology, tracks the levels of 4 subtypes of NK cells and suggests that these cells are good candidate biomarkers for disease progression.